PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Somatostatin analogs - Market size and forecast 2018-2023 Targeted therapies - Market size and forecast 2018-2023 Other therapies - Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors F. Hoffmann-La Roche Ltd Ipsen Pharma Merck & Co., Inc Novartis AG Pfizer Inc. PART 14: APPENDIX Research methodology List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Type - Market share 2018-2023 (%) Exhibit 18: Comparison by type Exhibit 19: Somatostatin analogs - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Somatostatin analogs - Year-over-year growth 2019-2023 (%) Exhibit 21: Targeted therapies - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Targeted therapies - Year-over-year growth 2019-2023 (%) Exhibit 23: Other therapies - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Other therapies - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by type Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in North America Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in Europe Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Impact of drivers and challenges Exhibit 44: Strategic alliances in global neuroendocrine tumors therapeutics market: Overview Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: F. Hoffmann-La Roche Ltd - Vendor overview Exhibit 51: F. Hoffmann-La Roche Ltd - Business segments Exhibit 52: F. Hoffmann-La Roche Ltd - Organizational developments Exhibit 53: F. Hoffmann-La Roche Ltd - Geographic focus Exhibit 54: F. Hoffmann-La Roche Ltd - Segment focus Exhibit 55: F. Hoffmann-La Roche Ltd - Key offerings Exhibit 56: F. Hoffmann-La Roche Ltd - Key customers Exhibit 57: Ipsen Pharma - Vendor overview Exhibit 58: Ipsen Pharma - Business segments Exhibit 59: Ipsen Pharma - Organizational developments Exhibit 60: Ipsen Pharma - Geographic focus Exhibit 61: Ipsen Pharma - Segment focus Exhibit 62: Ipsen Pharma - Key offerings Exhibit 63: Ipsen Pharma - Key customers Exhibit 64: Merck & Co., Inc - Vendor overview Exhibit 65: Merck & Co., Inc - Business segments Exhibit 66: Merck & Co., Inc - Organizational developments Exhibit 67: Merck & Co., Inc - Geographic focus Exhibit 68: Merck & Co., Inc - Segment focus Exhibit 69: Merck & Co., Inc - Key offerings Exhibit 70: Merck & Co., Inc - Key customers Exhibit 71: Novartis AG - Vendor overview Exhibit 72: Novartis AG - Business segments Exhibit 73: Novartis AG - Organizational developments Exhibit 74: Novartis AG - Geographic focus Exhibit 75: Novartis AG - Segment focus Exhibit 76: Novartis AG - Key offerings Exhibit 77: Novartis AG - Key customers Exhibit 78: Pfizer Inc. - Vendor overview Exhibit 79: Pfizer Inc. - Business segments Exhibit 80: Pfizer Inc. - Organizational developments Exhibit 81: Pfizer Inc. - Geographic focus Exhibit 82: Pfizer Inc. - Segment focus Exhibit 83: Pfizer Inc. - Key offerings Exhibit 84: Pfizer Inc. - Key customers Exhibit 85: Validation techniques employed for market sizing

F. Hoffmann-La Roche Ltd Ipsen Pharma Merck & Co., Inc Novartis AG Pfizer Inc.